Immunovant Inc

NASDAQ:IMVTUnited States

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.

Contact Information

Headquarters

320 West 37Th StreetNEW YORK, NY, United States 10018

Phone

917-580-3099

Fax

302-636-5454

Executives

Executive Chairman of the Board

Frank Torti

Chief Executive Officer of IMVT Corporation, Director

Peter Salzmann

Chief Financial Officer

Eva Barnett

Chief Technology Officer

Jay Stout

Chief Development Officer

Julia Butchko